Robert Dickey

Mr. Robert Dickey is a Chief Financial Officer at Vyome Holdings, Inc., a Chief Financial Officer at Exxel Pharma, Inc., a Chief Financial Officer at AIM ImmunoTech, Inc. and a Chief Financial Officer & Director at SFA Therapeutics, Inc. He is on the Board of Directors at SFA Therapeutics, Inc. and GSNO Therapeutics, Inc. Mr. Dickey was previously employed as a Chief Financial Officer by Invitae Corp., a Chief Financial Officer by Enveric Biosciences, Inc., an Independent Director by AngioGenex, Inc., an Independent Director by Emmaus Life Sciences, Inc., a Chief Financial Officer by NLS Pharmaceutics Ltd., a Managing Director by Danforth Advisors LLC, a Chief Financial Officer by Motif Bio Plc, a Chief Financial Officer & Vice President-Finance by Tyme Technologies, Inc., a Chief Financial Officer by Tyme, Inc., a Chief Financial Officer by NeoStem, Inc., a Senior Vice President by Hemispherx Biopharma, Inc., a Chief Financial Officer & Senior Vice President by StemCyte, Inc., a Chief Financial Officer by Locus Pharmaceuticals, Inc., a Chief Financial Officer by BeyondSpring Pharmaceuticals, Inc., a Managing Director by Legg Mason Wood Walker, Inc., a Managing Director by Lehman Brothers, Inc., a Principal by Neuromedical Systems, Inc., and a Chief Executive Officer & Chief Operating Officer by Protarga, Inc. He also served on the board at EMI Holding, Inc. and Sanuthera, Inc. He received his undergraduate degree from Princeton University and an MBA from The Wharton School of the University of Pennsylvania.